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Objectives: Right-sided circulatory failure resulting from severe preopera- 
tive pulmonary hypertension is a source of mortality early after cardiac 
transplantation. We undertook the present study (1) to analyze the 
association of elevated pulmonary hemodynamic indices with 30-day mor- 
tality, (2) to define threshold ranges associated with an increase in 30-day 
mortality, and (3) to evaluate the effect of vasodilator eversibility on 
30-day mortality. Methods: Preoperative hemodynamic profiles were evalu- 
ated in 476 patients who ultimately underwent cardiac transplantation. 
From these data, receiver-operating characteristic curves and stratum- 
specific likelihood ratios were generated to compare the efficacy of each 
hemodynamic index. A subset of patients with elevated hemodynamic 
profiles at baseline additionally underwent graded sodium nitroprusside 
infusion. Results: Analysis of receiver-operating characteristic curves dem- 
onstrated no statistically significant difference among the indices in their 
ability to predict 30-day mortality. Analysis of stratum-specific l kelihood 
ratios demonstrated three risk strata that correlated with significant 
differences in 30-day mortality, with patients in the high-risk stratum 
having a 3.2 to 4.4 increase in odds of 30-day mortality when compared with 
patients in the low-risk stratum. Nitroprusside data demonstrated that 
although 30-day mortality was better in patients with reversible pulmonary 
hypertension than in those with fixed pulmonary hypertension, it was not 
comparable with that of patients without pulmonary hypertension at 
baseline. Conclusions: Candidates for cardiac transplantation may be 
categorized into three risk strata on the basis of their preoperative 
pulmonary hemodynamic profile; the association of this profile with 30-day 
mortality is not linear. Reversibility with nitroprusside appears to confer 
some improvement in the risk of 30-day mortality, but it may not eliminate 
the risk entirely. (J Thorac Cardiovasc Surg 1997;114:627-34) 
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D espite advances in perioperative management, right-sided circulatory failure remains a signifi- 
cant source of morbidity and mortality early after 
cardiac transplantation. >s Previous investigators 
have suggested that severe pulmonary hypertension 
can result in right-sided circulatory failure because 
of a marked increase in afterload presented abruptly 
to the donor right ventricle. 4-v Thus preoperative 
pulmonary hypertension currently is a relative con- 
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traindication to cardiac transplantation at many 
centers worldwide, s'9 
Transplant physicians traditionally have placed 
great emphasis on calculated estimates of pulmo- 
nary hypertension (pulmonary vascular resistance 
[PVR], pulmonary vascular esistance index [PVRI] 
and transpulmonary gradient [TPG]) in the preop- 
erative evaluation of candidates for cardiac trans- 
plantation. However, since the first reports docu- 
menting a relationship between an elevated PVR 
and the risk of death from acute right ventricular 
failure, substantial controversy has persisted regard- 
ing the power of individual hemodynamic indices to 
predict perioperative mortality accurately. 1-7 Some 
investigators have additionally suggested that pa- 
tients may be subdivided on the basis of "fixed" or 
"reactive" components o their pulmonary hyperten- 
sion, the relative proportions of which may be 
determined by the use of pulmonary vasodilator 
therapy such as sodium nitroprusside, m 
Receiver-operating characteristic (ROC) curves 
have enjoyed increasing clinical application in the 
assessment of the predictive ability of a given test, This 
analysis is useful when a test result is represented on a 
continuous scale and more than one possible threshold 
value exists to define a positive and negative result. 11 
The area under the ROC curve reflects an estimate of 
the overall accuracy of a given test over its entire range 
of values and thereby represents a means by which the 
discrimination of individual tests may be compared, t2
Stratum-specific likelihood ratios (SSLRs), derived 
from data with which ROC curves are constructed, 
may be used to determine threshold values that more 
precisely distinguish cohorts of patients with different 
outcomes. 13
We retrospectively analyzed the preoperative car- 
diac catheterization data from patients undergoing 
transplantation at our institution between 1983 and 
1994 to determine whether an association exists 
between individual elevated preoperative pulmo- 
nary hemodynamic indices and 30-day all-cause 
mortality. Second, using ROC curve analysis, we 
compared the relative ability of each individual 
index to predict perioperative mortality to deter- 
mine whether any individual index is superior in its 
predictive ability. Third, from these ROC curves we 
derived SSLRs to delineate better threshold ranges 
that define an "elevated" preoperative hemody- 
namic profile. Last, we evaluated a subgroup of 
patients who underwent vasodilator "challenge" to 
compare the 30-day mortality of patients who had 
fixed pulmonary hypertension with that of both 
patients with reversible pulmonary hypertension and 
patients in the entire cohort who had no preopera- 
tive pulmonary hypertension. 
Methods 
Patient population. From April 1983 through June 
1994, a total of 671 patients underwent heart transplant 
procedures atthe Columbia-Presbyterian Medical Center. 
For 476 (70.9%) of these patients, complete preoperative 
hemodynamic data were available from which to evaluate 
the association between perioperative mortality and the 
calculated pulmonary hemodynamic indices PVR, PVRI. 
and TPG. All patients received eyelosporine-based immu- 
nosuppression (INN: cMosporin), and 30-day all-cause 
mortality was used as the end point of the study. Pre- 
sumed causes of death were obtained by a retrospective 
review of the clinical data by an investigator blinded to the 
preoperative h modynamic assessment. Patients excluded 
from transplantation (and this cohort) on the basis of 
pulmonary hypertension were those with a fixed PVRI of 
6.0 WU/m 2 or greater. 
Cardiac catheterization. Right heart catheterization 
was performed with the use of a balloon-tipped flow- 
directed catheter. For those patients with multiple cardiac 
catheterization procedures, the values obtained closest o 
the time of transplantation were chosen for further anal- 
ysis. Hemodynamic parameters including right atrial, pul- 
monary artery, and pulmonary capillary wedge pressures 
were obtained according to standard clinical methods. 
Body surface area was calculated frona height and weight, 
cardiac output was measured by thermodilution with iced 
injection solution, cardiac index was calculated from 
cardiac output and body surface area, and pulmonary 
hemodynamic indices were calculated by means of the 
following equations: 
tPA mean - PCW 
PVR (WU) - 
CO 
PVRI (WU • m 2) = 
tPA mean PCW) 
CI = PVR. BSA 
TPG (mm Hg) = PA mean - PCW 
where PA is pulmonary artery pressure, PCW is pulmo- 
nary capillary wedge pressure, CO is cardiac output, CI is 
cardiac index, and BSA is body surface area. 
Nitroprnsside protocol. Complete catheterization data 
obtained before and after the standard graded adminis- 
tration of sodium nitroprusside were available for 119 
patients with abnormal pulmonary hemodynamics (as 
defined by a PVR -> 2.5 WU or a systolic PA pressure >-- 
50 mm Hg). Intravenous nitroprusside therapy was begun 
at a dose of approximately 25 /xg/min. Hemodynamie 
measurements were obtained at rest before the adminis- 
tration of nitroprusside and then were monitored at 
regular intervals. The dose of nitroprusside was increased 
rapidly until there was (1) a decrease in PVR below 2.0 
WU, (2) a decrease in PA systolic pressure below 50 turn 
Hg, or (3) a decrease in mean blood pressure below 65 
mm Hg. 
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Table I. Demographic profile of the entire cohort and of 30-day survivors and nonsurvivors 
Entire cohort Nonsurvivors Survivors 
(n = 476) (n = 47) (n = 429) p Value 
Sex 
Male 379 (79.6%) 35 (74.5%) 344 (82.0%) 
Female 97 (20.4%) 12 (25.5%) 85 (19.8%) 
Age (mean ± SD) 47.8 _ 13.3 49.2 +_ 12.9 47.6 --_ 13.3 
Range 2.1-68.9 15.7-67.4 2.1-68.9 
Indicati0n for transplantation 
Coronary artery disease 179 (37.6%) 13 (27.7%) 166 (38.7%) 
Idiopathic ardiomyopathy 252 (52.9%) 26 (55.3%) 266 (52.7%) 
Viral cardiomyopathy 17 (3.6%) 5 (10.6%) 12 (2.8%) 
Congenital heart disease 10 (2,1%) 3 (6.4%) 1 (0.2%) 




NS, Not significant; SD, standard eviation. 
*p > 0.05 for comparison of survivors versus nonsurvivors for the given parameter. 
Table I I .  Baseline hemodynamic data for the entire cohort and of 30-day survivors and nonsurvivors 
Entire cohort Nonsurvivors Survivors 
(n = 476) (n = 47) (n = 429) p Value* Difference of mean 95% CI 
PA mean 31.5 +_ 11.4 35.9 + 1013 31.0 +_ 11.4 0.005 -4.9 -8.3~-1.4 
PCW 20.9 + 9.0 22.3 +_ 8.0 20.7 + 9.6 0.27 -1.6 -4.4-1.2 
Cardiac output 4.0 +_ 1.4 4,0 _+ 1.4 3.9 ± 1.4 0.64 -0.1 -0.5-0.3 
Calculated indices 
PVR 3.1 + 2.1 3.8 + 2.0 3.0 --- 2.1 0,010 -0.8 -1.4--0.17 
PVRI 5.5 +_ 3.7 6.9 ± 3.5 3.4 _+ 3.6 0.0001 -3.5 -4.6--2.4 
TPG 10.7 ± 5.9 13.5 +_ 6.1 10.4 ± 5.8 0.0006 -3.1 -4.9--1.3 
PA, Pulmonary artery pressure; PCW, pulmonary capillary wedge pressure. 
*p Value reflects Student's t test for unpaired samples comparing survivors versus nonsurvivors. 
Statistics 
ROC curves. X z Analysis and Student's t tests were used 
to compare categoric and continuous data from 30-day 
survivors and nonsurvivors, without adjustment for multi- 
ple comparisons. ROC curves were generated by plotting 
sensitivity on the ordinate and 1-specificity on the abscissa 
with the use of individual pulmonary hemodynamic ndi- 
ces for the prediction of 30-day mortality. 11' 12 Curves 
were generated with the use of data cut-points at regular 
intervals. The area under each ROC curve was derived 
from the Wilcoxon statistics. H 
A logistic regression analysis was also performed with 
30-day survival as the dependent variable and with PVR. 
PVRI. and TPG as independent variables. The score X z 
statistic associated with each independent variable de- 
scribes the relative strength of the relationship between 
each hemodynamic variable and 30-day survival; the vari- 
able with the highest score X 2 would be selected for model 
inclusion in a stepwise regression. The overall strength of 
each model is best described by the c statistic, which is the 
probability that a patient with an elevated PVR (or PVRI 
or TPG) will have a greater predicted probability of 
30-day mortality than a randomly selected patient with a 
less elevated PVR (or PVRI or TPG). This statistic is 
mathematically identical to the area under the ROC 
curve. 
SSLRs SSLRs and 95% confidence intervals were gen- 
erated for 30-day all-cause mortality, for strata of PVR, 
PVRI. and TPG, with the use of regular increments 
specific to the indices (PVR: 1 WU increments; PVRI: 1 
WU" m 2 increments; TPG: 1 mm Hg increments). SSLRs 






where Xag - the number of persons who died at less than 
30 days' follow-up after transplantation in the gth stratum 
of the given pulmonary hemodynamic ndex, ~1 = the 
total number of persons who died at less than 30 days' 
follow-up after transplantation, Xog - the number of 
persons who are alive at 30 days ~ follow-up or more after 
transplantation in the gth stratum of the given pulmonary 
hemodynamtc index, 4o - the ,total number of persons 
who are alive at 30 days' follow-up or more after trans- 
plantation, and where Xlg/~l - the probability of being in 
the gth stratum of a given pulmonary hemodynamic index 
given that one has died at less than 30 days' follow-up 
after transplantation a d Xog/r/o = the probability of being 
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Fig. 1. ROC curves and the associated area under the 
curve (A UC) for PVR. 
in the gth stratum of a given pulmonary hemodynamic 
index given that one is alive at 30 days' follow-up or more 
after transplantation. 
Ninety-five percent confidence intervals were calculated 
as follows: 
SSLR~, SSLRL = e lnssLR ± 1.96 ~/Var(lnSSLR) 
where 
1 1 1 
Var(lnSSLR) - + Xlg + 0.5 ~1 + 0.5 Xog + 0.5 
1 
r~0 + 0.5 
By combining adjacent strata with statistically indistinct 
SSLRs (i.e., those with overlapping 95% confidence inter- 
vals), we determined threshold values for the three pul- 
monary hemodynamic indices. When only two statistically 
distinct strata could be formed, but the data suggested an 
intermediate risk strata, three strata were formed. Statis- 
tical significance was defined as a p value less than 0.05. 
Survival analysis and ROC curve area computations were 
performed with SAS (version 6.09) PROC LIFETEST 
and PROC NPAR1WAY (SAS Institute, Inc., Cary, 
N.C.). SSLRs were calculated with the use of a previously 
published macro for Microsoft Excel spreadsheets (Mi- 
crosoft Corporation, Redmond, Wash.). 13 Thus, for pa- 
tients with pulmonary hemodynamic indices in a given 
range, the SSLR represents he relative odds of death 
when compared with the whole cohort. 
Results 
Demographics. The demographic profile of the 
entire cohort and, separately, for 30-day survivors 
and nonsurvivors studied is depicted in Table I. No 
statistically significant differences were detected be- 
tween survivors and nonsurvivors on the basis of 
age, sex, or indication for transplantation. Baseline 
Table III. Presumed causes of  30-day mortality 
(n = 47) 
Cause No. 
Primary graft failure 13 
Acute right-sided circulatory failure 8 
Infection/sepsis 7 
Rejection 6 
Embolic episode 4 
Multisystem organ failure 2 
Hemorrhage 2 
Other 5 
hemodynamic data evaluated in the preoperative 
assessments of the cohorts are depicted in Table II. 
Forty-seven patients died during the 30-day periop- 
erative period. Presumed causes of death for pa- 
tients in this cohort are detailed in Table III. 
ROC curves. The score )(2 statistics associated 
with each hemodynamic variable were 5.29 for PVR 
(p = 0.022), 2.89 for PVRI (p = 0.089), and 12.10 
for TPG (p < 0.001). ROC curves and the corre- 
sponding area under the curve for each of the three 
hemodynamic indices are shown in Figs. 1 to 3. 
ROC curves and the corresponding areas under the 
curve 2 standard deviation for each of the three 
hemodynamic indices were 0.63 _+ 0.04 (PVR), 
0.62 + 0.04 (PVRI), and 0.67 _- 0.05 (TPG). These 
areas were not statistically significantly different. 
SSLRs. Data from SSLR analysis of the gener- 
ated ROC curves are represented in Table IV. As 
shown, data for each pulmonary hemodynamic n- 
dex could best be described as distributed over low, 
average, and high risk strata. SSLRs were signifi- 
cantly different for high versus low strata for PVR, 
PVRI, and TPG (p < 0.05). 
Baseline strata. With the use of a ~ analysis and 
the aforementioned threshold ranges to define risk 
strata for the cohort, we reviewed the data from the 
entire cohort to evaluate their associations with 
30-day mortality. These data are also represented in 
Table IV. 
Nitroprusside challenge, With the use of the 
aforementioned risk strata for data evaluation, the 
subcohort of patients undergoing nitroprusside chal- 
lenge was distributed into groups of patients who 
had pulmonary hemodynamic ndices that were in 
the higher risk strata at baseline and either nonre- 
versible (fixed) or reversible (reactive). Reversibility 
was defined differently for the purposes of two 
separate analyses (liberal and stringent criteria). For 
the liberal criteria (group B1), reversibility repre- 
sented a decrease with nitroprusside therapy from 
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Fig. 3. ROC curves and the associated area under the 
curve (A UC) for the TPG. 
the high or average risk strata at baseline to the low 
risk stratum. Those patients in the corresponding 
~ed category. (group A1) had hemodynamic indices 
that remained at the high or average risk strata with 
the administration of nitroprusside. 
With the use of stringent criteria (group B2), 
reversibility represented a decrease with nitroprus- 
side therapy from the high risk stratum at baseline 
to the low risk stratum. Those patients in the 
corresponding fixed category (group A2) had either 
no significant change with nitroprusside therapy 
from the high risk stratum or had a reduction from 
the high to the average risk stratum only. These data 
are depicted in Tables V and VI. 
Discussion 
Right-sided circulatory failure and its associated 
morbidity remains a substantial source of periopera- 
tive mortality for recipients of cardiac transplants) -7 
Because of this widely recognized association, extreme 
preoperative pulmonary hypertension (as evidenced 
by elevated pulmonary hemodynamic indices) has 
remained acontraindication to cardiac transplantation 
at many transplant centers worldwide. Despite this, 
significant controversy persists regarding which of the 
three major calculated indices (PVR, PVRI, or TPG) 
represents he most accurate predictor of periopera- 
tire mortality. 
Proponents of the use of the TPG have suggested 
that the PVR (and thus the PVRI), in using cardiac 
output in its calculation, may be unreliable because 
of inherent inaccuracies in the measurement of 
cardiac output by thermodilution, particularly at low 
cardiac outputs. 14 The TPG, it is argued, is flow- 
independent and thus may better eflect resistance 
to flow across the pulmonary bed. 5 In contrast, 
others have argued that the gradient across the 
pulmonary bed itself is flow-dependent and thus 
requires that total flow (or cardiac output) be con- 
sidered in its interpretation. Additionally, Addoni- 
zio and associates 15have argued that the "indexed" 
PVR may more accurately estimate the degree of 
pulmonary resistance because it better accounts for 
variations in body size (especially important in the 
pediatric population). 
ROC curves may be plotted as a graphic repre- 
sentation of the relationship between sensitivity and 
specificity (the true-positive rate and the false- 
positive rate). The area under the ROC curve, or the 
probability that a randomly selected patient with an 
abnormal result will have a greater predicted prob- 
ability of a given outcome than a randomly selected 
patient with a normal result, may then be calculated 
to compare the overall discriminative accuracy of 
each hemodynamic ndex. Our data suggested that 
none of the indices was superior in its discrimination 
of perioperative mortality, a finding perhaps not 
surprising in that PVR and PVRI are derived from 
TPG. 
With any test whose results are represented on a 
continuous cale, the clinician hopes to optimize 
both sensitivity and specificity. ROC curves graphi- 
cally depict the relationship between the true- and 
false-positive rates and thus are an excellent method 
to determine the overall discriminative accuracy of a 
test measured on a continuous scale. SSLRs, derived 
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Table IV. Data from SSLR evaluation of ROC curve analysis 
Baseline strata 
Low risk Average risk High risk 
PVR 
Risk stratum range <2 WU 2-3 WU >3 WU 
SSLR* 0.46 (0.26-0.83) 0.97 (0.55-1.71) 1.62 (1.24-2.10) 
30-Day mortality 9/177 (5.1%)t  10/94 (10.6%) 28/158 (17.7%) 
PVRI  
Risk stratum range <4 WU • m ~ 4-7 WU • m 2 >7 WU.  rn 2 
SSLR* 0.52 (0.30-0.87) 1.i8 (0.78-1.79) 1.64 (1.14-2.37) 
30-Day mortal ity 11/194 (5.7%)t§ 16/124 (12.9%) 20/111 (18.0%) 
TPG 
Risk stratum range <10 mm Hg 10-14 mm Hg >14 mm Hg 
SSLR* 0.44 (0.27-0.74) 1.28 (0.81-2.03) 1.95 (1.38-2.75) 
30-Day mortality 11/226 (4.9%)t$ 14/100 (14.0%) 22/103 (21.4%) 
*p < 0.05, for comparison of SSLRs in high risk with low risk baseline strata groups (PVR = 0.04, PVRI = 0.05, and TPG = 0.02); data represented as SSLR 
(95% confidence interval). 
#p < 0.01, for comparison of 30-day mortality in high risk with low risk baseline strata groups (PVR = 0.002, PVRI = 0.004, and TPG = 0.0001) (difference 
of mean, 95% confidence interval): PVR (12.6, 5.9 to 19.4), PVRI (12.3, 4.5 to 20.2), and TPG (16.5, 8.1 to 24.9). 
~p = 0.02, for comparison of 30-day mortality in low risk with average risk baseline strata groups for TPG (difference of mean, 95% confidence interval): PVR 
(5.5, -1.5 to 12.6), PVRI (7.2, 0.5 to 14.0), and TPG (9.1, 1.8 to 16.5). 
§p = 0.06, for comparison of 30-day mortality in low risk with average risk baseline strata groups for PVRI (difference of mean, 95% confidence interval): 
PVR (7.1, -1.5 to 15.7), PVRI (5.1, -4.1 to 14.4), and TPG (7.4, -3.1 to 17.8). 
Table V. Thirty-day mortality rates for patients with fixed and reactive pulmonary hypertension i the 
vasodilator subcohort and for patients without pulmonary hypertension i the entire cohort 
Group AI: Group BI: Group C: 
Fired pulmonary hypertension, Reactive pulmonary hypepCension, No pulmonary hypertension, 
nitroprusside cohort* nitroprusside cohort? entire cohort 
PVR 13/72 (18.1%) 6/25 (17.1%) 9/177 (5.1%) 
PVRI  11/61 (18.0%) 7/45 (15.5%) 11/194 (5.7%) 
TPG 15/70 (21.4%) 4/27 (14.8%) 11/226 (4.9%) 
Group A1 not significantly different (p > 0.05) from group B1 for all three indices (PVR = 0.92, PVRI = 0.98, and TPG = 0.74) (difference of mean, 95% 
confidence interval): PVR (-0.9, -16.2 to 14.4), PVRI (-2.5, -16.8 to 11.8), and TPG (-6.6, -23.1 to 9.9). 
Group B1 versus group C (PVR, p = 0.05; PVRI, p = 0.08; and TPG = 0.14) (difference of mean, 95% confidence interval): PVR (-12.1, -25.0 to 0.8), 
PVRI (9.9, -1.2 to 21.0), and TPG (-9.9, -23.6 to 3.7). 
Group A1 versus group C (PVR,p = 0.01; PVRI,p = 0.02; and TPG, p = 0.0004) (difference of mean, 95% confidence interval): PVR (-13.0, -3.5 to 22.4), 
PVRI (12.4, 2.2 to 22.5), and TPG (-16.6, -26.6 to -6.5). 
*High or average risk stratum at baseline; with nitroprusside there was either no change or a reduction to average stratum. 
tHigh or average risk stratum at baseline; with nitroprusside there was a reduction to low risk stratum. 
from these curves, reflect a powerful means by 
which accurate thresholds for these tests may be 
elucidated. The ability to combine strata on the 
basis of statistically indistinct adjacent SSLRs in our 
analysis not only helped to define different risk 
strata for associated mortality (rather than one 
arbitrarily defined threshold point, as had been 
historically used), but further refuted the notion of a 
continuous association between pulmonary hemody- 
namic indices and postoperative mortality. Our eval- 
uation revealed three risk strata that, when applied 
to the entire cohort data, were associated with 
differences in 30-day mortality. 
Some have suggested that patients may be subdi- 
vided further into those with fixed or reactive com- 
ponents to their pulmonary hypertension, the rela- 
tive proportions of which may be elucidated with the 
use of pulmonary vasodilator therapy such as so- 
dium nitroprusside. 1° Those patients with a high 
degree of reactivity to their pulmonary hypertension 
with this vasodilator challenge may have a large 
reversible component and, it is postulated, may 
subsequently have a perioperative mortality compa- 
rable with patients who have no preoperative pul- 
monary hypertension. Conversely, those patients 
whose pulmonary hypertension responds less well 
may have a larger fixed component that may ad- 
versely affect heir posttransplantation outcome. 
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Table VI. Thirty-day mortality rates for patients with fixed and "reactive" pulmonary hypertension i the 
vasodilator subcohort and for patients without pulmonary hypertension i the entire cohort based on stringent 
criteria of reversibility 
Group A2: Group B2: Group C: 
Fixed pulmonary hypertension, Reactive pulmonary hypertension, No pulmonary hypertension, 
nitroprusside cohort* nitroprusside cohort? entire cohort 
PVR 12/62 (19.4%) 3/22 (13.6%) 9/177 (5.1%) 
PVRI  9/46 (19.6%) 4/19 (21.1%) 11/194 (5.7%) 
TPG 11/48 (22.9%) 2/15 (13.3%) 11/226 (4.9%) 
Group A2 not significantly different (p > 0.05) from group B2 for all three indices (PVR = 0.32, PVRI = 0.91, and TPG = 0.85) (difference of mean, 95% 
confidence interval): PVR (-5.7, -23.1 to 11.7), PVRI (1.5, -20.1 to 23.1), and TPG (-9.6, -30.5 to 11.3). 
Group B2 not significantly different (p = 0.05) from group C for all three indices (PVR = 0.85, PVRI = 0.08, and TPG = 0.47) (difference of mean, 95% 
confidence interval): PVR (8.6, -6.1 to 23.3), PVRI (-13.9, -25.8 to 2.0), and TPG (-8.5, -25.9 to 9.0). 
Group A2 versus group C (PVR, p = 0.01; PVRI, p = 0.02; and TPG, p = 0.001) (difference of mean, 95% confidence interval): PVR (14.3, 3.9 to 24.6), 
PVRI (-15.4, -34.0 to 3.2), and TPG (-18.0, -30.3 to -5.8). 
*High risk stratum at baseline; with nitroprusside there was either no change or a reduction to average risk stratum. 
~'High risk stratum at baseline; with nitroprusside there was a reduction to low risk stratum. 
To evaluate the effect of reversibility on postop- 
erative outcome, we reviewed ata from a subcohort 
receiving vasodilator challenge whose pulmonary 
hemodynamic profile placed them in the higher risk 
strata at baseline. Because our previous data analy- 
sis (see Table IV) demonstrated no statistically 
significant difference in 30-day mortality between 
patients in the high and average risk strata, we 
initially defined reversibility (liberal criteria) as a 
decrement from either high or average risk strata at 
baseline to the low risk stratum with vasodilator 
therapy. 
The conclusions from this data evaluation are 
threefold. First, those patients in the nitroprusside 
cohort with fixed pulmonary hypertension (group 
A1) had a nearly fourfold increase in their incidence 
of mortality when compared with those patients in 
the entire cohort without preoperative pulmonary 
hypertension (group C). Second, those patients with 
reversible hypertension (group B1) appeared to 
have a relative reduction in their 30-day mortality 
when compared with those patients with fixed hy- 
pertension (group A1). Finally, those patients with 
reversible hypertension (group B1) still had a 
marked increase in mortality when compared with 
patients in the entire cohort without preoperative 
pulmonary hypertension (group C). These data sug- 
gested that any reduction in 30-day mortality asso- 
ciated with reversibility was mild; 30-day mortality 
for patients with reversible hypertension was more 
comparable with that of patients with fixed pulmo- 
nary hypertension than with that of patients without 
pulmonary hypertension. 
To establish whether a subcohort of patients 
existed for whom reversibility with vasodilator ther- 
apy had a more substantial impact on 30-day mor- 
tality, we proposed a more stringent criterion to 
define reversibility: a decrement from only the high 
risk stratum at baseline to the low risk stratum with 
nitroprusside (see Table VI). The conclusions from 
this analysis were less clear; only those in the fixed 
category (group A2) had a mortality rate that was 
statistically different from that of patients with no 
pulmonary hypertension atbaseline (group C). The 
lack of statistical significance between groups A2 
and B2 and groups B2 and C may reflect the small 
sample size of those patients who met the stringent 
criteria of reversibility (group B2). Although the 
mortality rate of those in group B2 appeared better 
than that of patients with fixed hypertension (group 
A2), it was still substantially higher than that of 
patients without pulmonary hypertension atbaseline 
(group C). The power of this final analysis will 
require a larger cohort of patients to confirm these 
findings. 
Our findings suggest hat transplant physicians 
must continue to monitor patients in the early 
postoperative period for complications related to 
right-sided circulatory failure despite preoperative 
reversibility of pulmonary hemodynamic indices. 
We encourage other transplant groups to report 
their experience regarding the prognostic signifi- 
cance of preoperative r versibility in the hopes that 
these difficult and contentious issues may be re- 
solved. 
Limitations. In this study, we chose to consider 
the association between increased preoperative pul- 
monary hemodynamic indices and all-cause 30-day 
mortality. In light of the underlying pathophysio- 
logic relationship between pulmonary hypertension 
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and right-sided circulatory failure, it could be ar- 
gued that only death resulting from right-sided 
circulatory failure should have been used as the 
outcome measure. Our decision to use all-cause 
30-day mortality as the outcome was based on the 
following considerations. A retrospective determi- 
nation of the cause of death is prone to error, 
particularly in the perioperative cardiac transplant 
setting. Right-sided circulatory failure may have 
contributed substantially to some patient deaths for 
which other causes were assigned retrospectively. 
For example, patients with right-sided circulatory 
failure were likely to have remained intubated and 
to have pulmonary artery catheters remain in place 
longer, rendering them more susceptible to poten- 
tially fatal pneumonia or line sepsis. Treatment of 
infections may have mandated a decrease in immu- 
nosuppression, placing such patients at increased 
risk for fatal allograft rejection. 
Inasmuch as no firm quantitative definition of 
right-sided circulatory failure has been established, 
its diagnosis is essentially subjective. The use of 
30-day all-cause mortality, an unequivocal end 
point, was preferable to dependence on a retrospec- 
tive assignment of causes of death. Our inclusion of 
deaths that were unlikely to have resulted from right 
ventricular failure biases our results against finding 
the associations we did and thus strengthens the 
conclusions that can be drawn from these results. 
This was a retrospective study spanning more 
than a decade of transplant recipients. Thus patient 
medications at the time of catheterization were not 
prospectively recorded and were not available for 
analysis. However, optimization of the medical reg- 
imen was routine before catheterization. 
Last, the power of some analyses was limited by 
relatively small sample sizes. These analyses hould 
be repeated prospectively in larger cohorts to con- 
firm our results. 
We thank John C. Pierce, MD, MA, MS, for kindly 
providing the Microsoft Excel macro used to calculate 
stratum-specific l kelihood ratios. 
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